

February 4, 2015

Listing Department,
NATIONAL STOCK EXCHANGE OF INDIA LIMITED,
Exchange Plaza
Bandra Kurla Complex
Bandra (E)
MUMBAI - 400 051

Dear Sir,

Sub: **Outcome of the Board Meeting**

Ref: Company Code No.AUROPHARMA

The Board at the Meeting held on 4th February, 2015 approved the proposal for setting up a Joint Venture (JV) with Tergene Biotech Private Limited, a vaccine development company based in India. Tergene works on development of the Pneumococcal Conjugate Vaccine (PCV) through use of cutting edge vaccine technology compressing time and cost, thereby making such vaccine available at an affordable cost. PCV is a commercially available vaccine with limited competition and a global branded market of more than USD 5 billion. Aurobindo will hold a majority stake in the JV and will fund the product development in a phased manner spanning over three years. The financial terms are subject to entering into definitive agreements.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED



A.MOHAN RAMI REDDY
AVP (Legal) & Company Secretary



AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad - 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059
Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com